CAJ | 학술논문

目的评估EBV血请学筛查NPC的效果、EB病毒阳性人群和阴性人群鼻咽癌发生的危险.方法免疫酶法检测30～59岁42 048人血清EB病毒抗体VCA/IgA、EA/IgA,抗体滴度均≥1/5为阳性.所有人群随访至1999年底.结果筛查第1年检出45例鼻咽癌(45/42 048,107.02/105),随后12年,3050例VCA/IgA阳性人群鼻咽癌平均发病率(每年144.86/105)高于38 953阴性人群(每年11.98/105) ,检出的154例鼻咽癌Ⅰ期72例.结论如以往报道,EB病毒血清学确实可以检出早期鼻咽癌.在首轮筛查后的12年中,VCA/IgA阳性人群鼻咽癌发病危险是阴性人群的12倍.Ⅰ期鼻咽癌放疗后5年、10年生存率(81.25%, 67.39%)显著高于Ⅱ-A、Ⅱ-B和Ⅲ期鼻咽癌(60.32%, 26.67%).
목적평고EBV혈청학사사NPC적효과、EB병독양성인군화음성인군비인암발생적위험.방법면역매법검측30～59세42 048인혈청EB병독항체VCA/IgA、EA/IgA,항체적도균≥1/5위양성.소유인군수방지1999년저.결과사사제1년검출45례비인암(45/42 048,107.02/105),수후12년,3050례VCA/IgA양성인군비인암평균발병솔(매년144.86/105)고우38 953음성인군(매년11.98/105) ,검출적154례비인암Ⅰ기72례.결론여이왕보도,EB병독혈청학학실가이검출조기비인암.재수륜사사후적12년중,VCA/IgA양성인군비인암발병위험시음성인군적12배.Ⅰ기비인암방료후5년、10년생존솔(81.25%, 67.39%)현저고우Ⅱ-A、Ⅱ-B화Ⅲ기비인암(60.32%, 26.67%).
Objective To evaluate the efficiency of Epstein-Barr viral serology in detecting nasopharyngeal carcinoma (NPC) and comparing the NPC risks between serology-positive and serology-negative subjects.Conclusion This reveals that EBV serology could actually detect early-stage NPCs as previously reported. Meaningfully, the NPC risk increased 12 times the VCA-IgA-negative subjects in the VCA-IgA-positive subjects after the first-turn serological screening.The 5-year and 10-year survival rates of stage-I NPC patients (81.25%, 67.39% respectively) were both significantly higher than those of the stage-ⅡA, stage-ⅡB and stage-Ⅲ patients (60.32%, 26.67% respectively) after radiotherapy.